Ficha bibliográfica
Dziedowiec, E., Nayak, S. U., Gruver, K. S., Jennings, T., Tallarida, C. S., & Rawls, S. M.
(2018). Mu Opioid Receptor Agonist DAMGO Produces Place Conditioning, Abstinence-induced Withdrawal, and Naltrexone-Dependent Locomotor Activation in Planarians. Neuroscience,386, 214-222. doi:10.1016/j.neuroscience.2018.06.029
Ghelardini, C., Di Cesare, L., & Bianchi, E. (2015). The pharmacological basis of opioids.
Clinical Cases in Mineral and Bone Metabolism,12(3), 219-221. doi:10.11138/ccmbm/2015.12.3.219
Hang, A., Wang, Y., He, L., & Liu, J. (2015). The role of the dynorphin/κ opioid receptor
system in anxiety. Acta Pharmacologica Sinica,36(7), 783-790. doi:10.1038/aps.2015.32
Hemmings A., Parker M.O., Hale C., McBride S.D. (2018). Causal and functional
interpretation of mu- and delta-opioid receptor profiles in mesoaccumbens and nigrostriatal pathways of an oral stereotypy phenotype. Behavioural Brain Research. https://doi.org/10.1016/j.bbr.2018.06.031
Holzer, P. (2014). Pharmacology of Opioids and their Effects on Gastrointestinal Function.
The American Journal of Gastroenterology Supplements,2(1), 9-16. doi:10.1038/ajgsup.2014.4
Levy-Cooperman, N., Mcintyre, G., Bonifacio, L., Mcdonnell, M., Davenport, J. M.,
Covington, P. S., Sellers, E. M. (2016). Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed - and -Opioid Receptor Agonist and -Opioid Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics,359(3), 471-481. doi:10.1124/jpet.116.236547
Manglik, A., Lin, H., Aryal, D. K., Mccorvy, J. D., Dengler, D., Corder, G., . . . Shoichet, B.
K. (2016). Structure-based discovery of opioid analgesics with reduced side effects. Nature, 537(7619), 185-190. doi:10.1038/nature19112
Margolis, E. B., Fujita, W., Devi, L. A., & Fields, H. L. (2017). Two delta opioid receptor
subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor. Neuropharmacology,123, 420-432. doi:10.1016/j.neuropharm.2017.06.019
Meyer, J. S., Quenzer, L. F., & Yates, J. R. (2018). Psychopharmacology: Drugs, the brain,
and behavior (3rd ed.). New York: Oxford University Press.
Minervini, V., Dahal, S., & France, C. P. (2016). Behavioral Characterization of κ Opioid
Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats. Journal of Pharmacology and Experimental Therapeutics,360(2), 280-287. doi:10.1124/jpet.116.235630
Peciña, M., Karp, J. F., Mathew, S., Todtenkopf, M. S., Ehrich, E. W., & Zubieta, J. (2018).
Endogenous opioid system dysregulation in depression: Implications for new therapeutic approaches. Molecular Psychiatry. doi:10.1038/s41380-018-0117-2
Price, R. C., Christou, N. V., Backman, S. B., Stone, L., & Schweinhardt, P. (2016).
Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals. Psychopharmacology,233(23-24), 3869-3879. doi:10.1007/s00213-016-4417-4
Richard, J. M., & Fields, H. L. (2016). Mu-opioid receptor activation in the medial shell of
nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement. Neuropharmacology,108, 14-23. doi:10.1016/j.neuropharm.2016.04.010
Wang, D., Tawfik, V. L., Corder, G., Low, S. A., François, A., Basbaum, A. I., & Scherrer,
G. (2018). Functional Divergence of Delta and Mu Opioid Receptor Organization in CNS Pain Circuits. Neuron,98(1). doi:10.1016/j.neuron.2018.03.002
